A Review on Nanotechnology based In Situ Gelling System as a Reliable Weapon for Targeting Alzheimer's Disease via Intranasal Route.

Abstract

A recent World Health Organization report claims that along with the growing world population and emerging life prospects, the prevalence of neurological disorders is also increasing. Out of all neurological disorders, Alzheimer's disease is the most widespread and alarming concern. The disease poses significant therapeutic challenges due to the blood-brain barrier's restrictiveness and the lack of effective drug delivery systems. The olfactory and trigeminal nerves have direct access to the brain, therefore, intranasal drug delivery can be a promising route for the direct delivery of anti-Alzheimer's drugs. Despite this advantage, brain targeting is limited through this route due to mucociliary clearance. Thus, in situ, nanotechnology offers a transformative approach by leveraging the intranasal route to directly target the central nervous system. This comprehensive review discusses recent advancements, mechanisms, and applications of in situ nanotechnology in Alzheimer's disease therapeutics, highlighting its potential to enhance drug delivery efficiency, improve bioavailability, and mitigate the progression of this debilitating condition. The importance of intranasal drug delivery has been emphasized in this review, along with the clear benefits of in situ lipid- based nanotechnology for the efficient delivery of medication in targeting Alzheimer's disease.